Skip to main content
. 2019 Apr 7;24(7):1363. doi: 10.3390/molecules24071363

Figure 5.

Figure 5

Effect of ponatinib on the protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) signaling pathway. (A) Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR. (B) Time course of ponatinib (1 μM) effect on the phosphorylation of Akt and mTOR. (C) Effect of ponatinib on SK-Hep-1 cell viability in the presence and absence of mTOR inhibitors, temsirolimus and rapamycin. (D) Effect of ponatinib on SNU-423 cell viability in the presence and absence of mTOR inhibitors, temsirolimus and rapamycin. (E) Effect of ponatinib on SK-Hep-1 cell viability in the presence and absence of an Akt inhibitor, MK-2206. (F) Effect of ponatinib on SNU-423 cell viability in the presence and absence of an Akt inhibitor, MK-2206.